Eric A. Epping

Dr. Eric A. Epping

orcid

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2016 in American Journal of Psychiatry
Verified
Journal Article
Closed access
EEEric A. Epping
Eric A. Epping
JKJi-In Kim
Ji-In Kim
DCDavid Craufurd
David Craufurd
TBThomas M. Brashers-Krug
Thomas M. Brashers-Krug
KAKaren E. Anderson
Karen E. Anderson
CGCoordinators of the Huntington Study Group
Coordinators of the Huntington Study Group

1 July 1995 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
ADAnabelle Decottignies
Anabelle Decottignies
LLLaurence Lambert
Laurence Lambert
PCPatrice Catty
Patrice Catty
HDHervé Degand
Hervé Degand
EEEric A. Epping
Eric A. Epping
AGAndré Goffeau
André Goffeau
The SNQ2 gene of Saccharomyces cerevisiae, which encodes an ATP binding cassette protein responsible for resistance to the mutagen 4-nitroquinoline oxide, is regulated by the DNA-binding proteins PDR1 and PDR3. In a plasma membrane-enriched fraction from a pdr1 mutant, the SNQ2 protein is found in the 160-kDa overexpressed band, together with PDR5. The SNQ2 protein was solubilized with n-dodecyl β-D-maltoside from the plasma membranes of a PDR5-deleted strain and separated from the PMA1 H-ATPase by sucrose gradient centrifugation. The enzyme shows a nucleoside triphosphatase activity that differs biochemically from that of PDR5 (Decottignies, A., Kolaczkowski, M., Balzi, E., and Goffeau, A.(1994) J. Biol. Chem. 269, 12797-12803) and is sensitive to vanadate, erythrosine B, and Triton X-100 but not to oligomycin, which inhibits the PDR5 activity only. Disruption of both PDR5 and SNQ2 in a pdr1 mutant decreases the cell growth rate and reveals the presence of at least two other ATP binding cassette proteins in the 160-kDa overexpressed band that have been identified by amino-terminal microsequencing.

10 January 2017 in Neurology
Verified
Journal Article
Closed access
PDF file
AMAndrew McGarry
Andrew McGarry
MMMichael McDermott
Michael McDermott
KKKarl Kieburtz
Karl Kieburtz
EBElisabeth A. de Blieck
Elisabeth A. de Blieck
FBFlint Beal
Flint Beal
MCMerit Cudkowicz
Merit Cudkowicz
Objective: To test the hypothesis that chronic treatment of early-stage Huntington disease (HD) with high-dose coenzyme Q10 (CoQ) will slow the progressive functional decline of HD. Methods: We performed a multicenter randomized, double-blind, placebo-controlled trial. Patients with early-stage HD (n = 609) were enrolled at 48 sites in the United States, Canada, and Australia from 2008 to 2012. Patients were randomized to receive either CoQ 2,400 mg/d or matching placebo, then followed for 60 months. The primary outcome variable was the change from baseline to month 60 in Total Functional Capacity score (for patients who survived) combined with time to death (for patients who died) analyzed using a joint-rank analysis approach. Results: An interim analysis for futility revealed a conditional power of <5% for the primary analysis, prompting premature conclusion in July 2014. No statistically significant differences were seen between treatment groups for the primary or secondary outcome measures. CoQ was generally safe and well-tolerated throughout the study. Conclusions: These data do not justify use of CoQ as a treatment to slow functional decline in HD. ClinicalTrials.gov identifier: NCT00608881. Classification of evidence: This article provides Class I evidence that CoQ does not slow the progressive functional decline of patients with HD.

1 December 1999 in Molecular and Cellular Biology
Verified
Journal Article
Closed access
PDF file
SCSean T. Coleman
Sean T. Coleman
EEEric A. Epping
Eric A. Epping
SSSusanne M. Steggerda
Susanne M. Steggerda
WMW. Scott Moye-Rowley
W. Scott Moye-Rowley
Positive regulation of gene expression by the yeastSaccharomyces cerevisiae transcription factor Yap1p is required for normal tolerance of oxidative stress elicited by the redox-active agents diamide and H2O2. Several groups have provided evidence that a cluster of cysteine residues in the extreme C terminus of the factor are required for normal modulation of Yap1p by oxidant challenge. Deletion of this C-terminal cysteine-rich domain (c-CRD) produces a protein that is highly active under both stressed and nonstressed conditions and is constitutively located in the nucleus. We have found that a variety of different c-CRD mutant proteins are hyperactive in terms of their ability to confer diamide tolerance to cells but fail to provide even normal levels of H2O2 resistance. Although the c-CRD mutant forms of Yap1p activate an artificial Yap1p-responsive gene to the same high level in the presence of either diamide or H2O2, these mutant factors confer hyperresistance to diamide but hypersensitivity to H2O2. To address this discrepancy, we have examined the ability of c-CRD mutant forms of Yap1p to activate expression of an authentic target gene required for H2O2 tolerance, TRX2. When assayed in the presence of c-CRD mutant forms of Yap1p, a TRX2-lacZfusion gene fails to induce in response to H2O2. We have also identified a second cysteine-rich domain, in the N terminus (n-CRD), that is required for H2O2 but not diamide resistance and influences the localization of the protein. These data are consistent with the idea that the function of Yap1p is different at promoters of loci involved in H2O2 tolerance from promoters of genes involved in diamide resistance.

6 March 2008 in Human Genetics
Verified
Journal Article
Closed access
PDF file
LDL. K. Davis
L. K. Davis
KMK. J. Meyer
K. J. Meyer
DRD. S. Rudd
D. S. Rudd
ALA. L. Librant
A. L. Librant
EEEric A. Epping
Eric A. Epping
TWT. H. Wassink
T. H. Wassink

3 September 2019 in Neurology
Verified
Journal Article
Closed access
PDF file
Ellen Van Der PlasEllen Van Der Plas
Ellen Van Der Plas
DLDouglas R. Langbehn
Douglas R. Langbehn
ACAmy L Conrad
Amy L Conrad
TKTimothy R. Koscik
Timothy R. Koscik
ATAlexander Tereshchenko
Alexander Tereshchenko
PNPeggy C. Nopoulos
Peggy C. Nopoulos
Objective The huntingtin gene is critical for the formation and differentiation of the CNS, which raises questions about the neurodevelopmental effect of CAG expansion mutations within this gene (mHTT) that cause Huntington disease (HD). We sought to test the hypothesis that child and adolescent carriers of mHTT exhibit different brain growth compared to peers without the mutation by conducting structural MRI in youth who are at risk for HD. We also explored whether the length of CAG expansion affects brain development. Methods Children and adolescents (age 6–18) with a parent or grandparent diagnosed with HD underwent MRI and blinded genetic testing to confirm the presence or absence of mHTT. Seventy-five individuals were gene-expanded (GE) and 97 individuals were gene-nonexpanded (GNE). The GE group was estimated to be on average 35 years from clinical onset. Following an accelerated longitudinal design, age-related changes in brain regions were estimated. Results Age-related striatal volume changes differed significantly between the GE and GNE groups, with initial hypertrophy and more rapid volume decline in GE. This pattern was exaggerated with CAG expansion length for CAG > 50. A similar age-dependent group difference was observed for the globus pallidus, but not in other major regions. Conclusion Our results suggest that pathogenesis of HD begins with abnormal brain development. An understanding of potential neurodevelopmental features associated with mHTT may be needed for optimized implementation of preventative gene silencing therapies, such that normal aspects of neurodevelopment are preserved as neurodegeneration is forestalled.